Overview of Voting Rights and Share Capital
In the world of corporate governance, understanding how voting rights and share capital function is crucial for investors and stakeholders. Companies, such as Nanobiotix, emphasize transparency in their operations to foster confidence among shareholders. This article delves into the intricacies of voting rights and shares capital, shedding light on the foundational aspects of ownership and influence within the company.
Current Share Structure
As of a recent reporting, Nanobiotix has revealed significant data regarding their shares outstanding and voting rights. The latest figures indicate that there are approximately 47,426,851 shares outstanding as of the end of April 2025. This figure plays a vital role in determining the number of voting rights available to shareholders.
Voting Rights Breakdown
The total number of voting rights, which is important for decision-making during shareholder meetings, stands at 49,535,883. Understanding the distinction between theoretical and exercisable voting rights is essential. Theoretical voting rights count all shares that have voting rights, including those that may not be currently active. In contrast, exercisable voting rights account for shares that shareholders can actively vote with, excluding those that may be suspended.
About Nanobiotix
Nanobiotix is at the forefront of the biotechnology sector, focusing on groundbreaking therapeutic methods designed to improve patient outcomes significantly. Founded in 2003 and headquartered in Paris, the company has been publicly listed on Euronext Paris since 2012 and the Nasdaq Global Select Market since 2020. They have established additional operations in Cambridge, Massachusetts, further reinforcing their commitment to innovation and excellence.
Patents and Research
The company holds over 25 patent families that encompass three principal nanotechnology platforms. These platforms target critical areas: oncology, bioavailability and biodistribution, and disorders of the central nervous system. This extensive research portfolio not only showcases their innovative approach but also highlights their dedication to enhancing treatment possibilities.
Corporate Philosophy and Objectives
At the heart of Nanobiotix's mission is the belief in transforming medical treatment landscapes through innovative strategies. They prioritize pushing beyond conventional limits, striving to enhance the possibilities for human life and improve the future of medical therapies. Their approach fosters a collaborative environment aimed at inspiring their team to make impactful contributions to healthcare.
Company Contact Information
For inquiries, stakeholders can reach out to the Communications or Investor Relations Departments. Located in Paris, the company offers direct communication channels to its executives, including Brandon Owens, VP of Communications, and Ricky Bhajun, Director of Investor Relations. This direct line of communication reinforces Nanobiotix’s commitment to shareholder engagement and transparency.
Frequently Asked Questions
What are the voting rights associated with shares at Nanobiotix?
Voting rights at Nanobiotix are calculated based on the number of shares outstanding, with specific numbers reflecting both theoretical and exercisable rights.
How many shares are currently outstanding for Nanobiotix?
As reported, there are 47,426,851 shares outstanding for Nanobiotix as of late April 2025.
What does the term 'exercisable voting rights' mean?
Exercisable voting rights refer to the total voting rights shareholders can actively use in meetings, excluding any shares that may have their voting rights suspended.
Where is Nanobiotix headquartered?
Nanobiotix is headquartered in Paris, France, with additional locations including Cambridge, Massachusetts.
What is the primary focus of Nanobiotix's research?
Nanobiotix focuses on innovative therapeutic solutions primarily within oncology, as well as improving bioavailability and addressing disorders of the central nervous system.
